Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence

被引:28
作者
Liu, Jia [1 ]
Fu, Jing [1 ]
Xu, Yuan [1 ]
Wang, Guang [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Endocrinol, Beijing 100020, Peoples R China
关键词
TSH-RECEPTOR ANTIBODIES; IODINE INTAKE; OPEN-LABEL; FOLLOW-UP; HYPERTHYROIDISM; RELAPSE; METHIMAZOLE; WITHDRAWAL; REMISSION; SELENIUM;
D O I
10.1155/2017/3813540
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graves' disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation exposure and invasive procedures. However, the relatively high recurrence rate is a major concern for ATD treatment, which is associated with multiple influencing factors like clinical characteristics, treatment strategies, and genetic and environmental factors. Of these influencing factors, some are modifiable but some are nonmodifiable. The recurrence risk can be reduced by adjusting the modifiable factors as much as possible. The titration regimen for 12-18 months is the optimal strategy of ATD. Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of ATD treatment and mainly focused on influencing factors for recurrence in GD patients with ATD treatment.
引用
收藏
页数:8
相关论文
共 100 条
[1]   Antithyroid drug regimen for treating Graves' hyperthyroidism [J].
Abraham, Prakash ;
Avenell, Alison ;
McGeoch, Susan C. ;
Clark, Louise F. ;
Bevan, John S. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)
[2]  
ALEXANDE.WD, 1965, LANCET, V2, P866
[3]  
ALFONSO GO, 1988, REV CLIN ESP, V183, P401
[4]   Age and gender predict the outcome of treatment for Graves' hyperthyroidism [J].
Allahabadia, A ;
Daykin, J ;
Holder, RL ;
Sheppard, MC ;
Gough, SCL ;
Franklyn, JA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (03) :1038-1042
[5]   ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION [J].
ALLANNIC, H ;
FAUCHET, R ;
ORGIAZZI, J ;
MADEC, AM ;
GENETET, B ;
LORCY, Y ;
LEGUERRIER, AM ;
DELAMBRE, C ;
DERENNES, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) :675-679
[6]   Predictors of long-term remission in patients with Graves' disease: a single center experience [J].
Anagnostis, Panagiotis ;
Adamidou, Fotini ;
Polyzos, Stergios A. ;
Katergari, Simoni ;
Karathanasi, Eleni ;
Zouli, Chrisanthi ;
Panagiotou, Athanasios ;
Kita, Marina .
ENDOCRINE, 2013, 44 (02) :448-453
[7]  
[Anonymous], 2016, COCHRANE DATABASE SY
[8]   Autoimmune thyroid disorders [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Corrado, Alda ;
Di Domenicantonio, Andrea ;
Fallahi, Poupak .
AUTOIMMUNITY REVIEWS, 2015, 14 (02) :174-180
[9]   Increase of Interferon-γ Inducible CXCL9 and CXCL11 Serum Levels in Patients with Active Graves' Disease and Modulation by Methimazole Therapy [J].
Antonelli, Alessandro ;
Ferrari, Silvia Martina ;
Corrado, Alda ;
Ferrannini, Ele ;
Fallahi, Poupak .
THYROID, 2013, 23 (11) :1461-1469